Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents

X
Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms Discover-1
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 15 Nov 2023 Results of post hoc analysis (n=1120) assessing the effect of Guselkumab on time to minimal clinically important improvements (MCII) in patients reported outcomes and composite measures of disease activity and assessed association between W4/W8 MCII achievement and later disease control (W24/W52), presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results assessing the agreement of PtGA and PhGA through week (W) 24 and identified factors driving disagreement between PtGA and PhGA using pooled data from the phase 3 DISCOVER (D)1 & 2 studies, presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results of post hoc pooled analysis assessing the relationships between blood neutrophils and clinical outcomes during treatment with the fully human IL-23p19-subunit inhibitor guselkumab from DISCOVER-1 & 2 trials, presented at the ACR Convergence 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top